Imatinib (Gleevec(R), Glivec(R)), a selective inhibitor of ABL, KIT, and PDGFRA/B, is the first line targeted therapy for gastrointestinal stromal tumor (GIST).Unfortunately, the median-progressionfree-survival (PFS) of unresectable locally advanced and metastatic GIST is < 2 years.Vemurafenib demonstrated excellent response rate in B-RAFV600-mutated-melanoma, however, the short medianPFS of< 9 months is disappointing.The vulnerability of developing drug-resistance using monotherapy and the nature of these two culprits prompted us to exploit antitumor immunity to overcome relapse.